Rocket Pharmaceuticals (RCKT) Change in Acquisitions & Divestments (2016 - 2026)

Rocket Pharmaceuticals has disclosed Change in Acquisitions & Divestments across 10 years of filings, most recently posting $66.2 million for Q1 2026.

• Change in Acquisitions & Divestments for Q1 2026 came in at $66.2 million, down 19.46% year-over-year; the trailing twelve-month figure through Mar 2026 was $364.8 million (changed 0.01% YoY), and the FY2025 annual result was $380.8 million, down 0.7% from the prior year.
• Change in Acquisitions & Divestments came in at $66.2 million for Q1 2026 at Rocket Pharmaceuticals, down from $91.0 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $123.0 million in Q3 2025 to a low of $50.8 million in Q4 2022.
• The 5-year median for Change in Acquisitions & Divestments is $82.3 million (2025), against an average of $83.1 million.
• Across the five-year window, Change in Acquisitions & Divestments decreased 23.97% in 2023 and jumped 62.05% in 2024, its largest moves.
• Rocket Pharmaceuticals' Change in Acquisitions & Divestments stood at $50.8 million in 2022, then jumped by 42.35% to $72.3 million in 2023, then grew by 19.54% to $86.5 million in 2024, then climbed by 5.22% to $91.0 million in 2025, then slipped by 27.2% to $66.2 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $66.2 million (Q1 2026), $91.0 million (Q4 2025), and $123.0 million (Q3 2025), per Business Quant data.